OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference
This in-person and virtual (hybrid) conference to be held September 12-14, 2022
ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held as a hybrid in-person and virtual event on September 12-14, 2022.
The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.
Oliver Schacht, CEO, and Albert Weber, CFO, will be available for in-person meetings at the conference, and management will provide an overview of the Company's business during the company’s presentation.
Those interested can listen to the Company’s presentation by registering for the conference at the following link ().
Over 500 corporate presentations and panels held at the conference will be available during September 12-14, 2022.Event: H.C. Wainwright 24th Annual Global Investment Conference (Hybrid Conference)
| Date: September 12-14, 2022 Presentation Day & Time: September 12, 2022 at 4:00 PM (ET) Location: In-person in Kennedy II – 4th Floor at the Lotte New York Palace Hotel, New York, NY |
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit. For more information, please visit .
Forward-Looking Statements
This press release includes statements regarding OpGen’s participation at the H.C. Wainwright 24th Annual Global Investment Conference. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright & Co. on the web at
OpGen:
Oliver Schacht
President and CEO
OpGen Press Contact:
Matthew Bretzius
FischTank Marketing and PR
OpGen Investor Contact:
Alyssa Factor
Edison Group
